AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2017
Jun 9, 2017
35334_dirs_2017-06-09_d6c22caa-d644-4525-a15c-5a3583c8302a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-06-08
Reporting Person: Equels Thomas K. (Director, CEO / President)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-06-08 | Options to buy Common Stock | $0.56 | J | 300000 | Acquired | 2027-06-08 | Common Stock (300000) | Direct |
Footnotes
F1: Stock Options issued per the employment agreement.